NCT06740786Not yet recruiting
Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
Source: ClinicalTrials.gov · Last updated 18 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Atrial fibrillation (AF) is a common arrhythmia, particularly prevalent in the elderly population. Catheter ablation is a common treatment for AF, but post-ablation recurrence of arrhythmias remains a significant clinical challenge. Dapagliflozin, an SGLT2 inhibitor primarily used for the treatment of type 2 diabetes, has shown potential in the field of cardiology, particularly for treating heart failure patients. Some studies suggest that dapagliflozin may reduce cardiac workload, improve heart function, and could even help in the management of atrial fibrillation. Therefore, this study aims to explore whether dapagliflozin can reduce the recurrence of arrhythmias following atrial fibrillation catheter ablation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 6 Dec 2024
- Start date
- 10 Dec 2024
- Primary completion date
- 1 May 2026
- Lead sponsor
- Xu Liu
- Diseases
- Atrial fibrillation
- NCT number
- NCT06740786
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 10 Dec 2024 to the primary completion date, 1 May 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Presence of urinary tract infection Pregnancy or Breastfeeding: Women who are pregnant, breastfeeding, or planning to become pregnant.
- Allergy to Dapagliflozin or Similar Drugs: History of allergic reactions to dapagliflozin or other SGLT2 inhibitors.
Lab values
- Kidney Function: eGFR \< 45 ml/min/1.73m², with severe kidney disease.
Other
- Other Contraindications to Dapagliflozin: Any other contraindications for dapagliflozin use.
Who the study is looking for
- \- Age: Patients aged 18 years and older. Presence of type 2 diabetes or heart failure. Diagnosis of Atrial Fibrillation: Confirmed atrial fibrillation through ECG or Holter monitoring.
- First-time Catheter Ablation: Patients undergoing their first atrial fibrillation catheter ablation.
- Voluntary Participation: Patients willing to participate and sign informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.